Talimogene laherparepvec was well tolerated with no maximum-tolerated dose reached (which enabled a multi-dosing schedule to be defined) and biological activity (virus replication, GM-CSF expression, local reactions, and HSV-1 antigen-associated tumor necrosis) was observed [24]. The gene discussed is CSF2; the disease is neoplasm.